A Study of LY3502970 in Participants With Normal and Impaired Renal Function

NCT05936138 · Completed

Last updated 2026-05-28

This study tests the effects of the drug LY3502970 on people with normal and impaired kidney function to see how the body processes it.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 24 people

Who can join Ages 18–85 · all sexes Healthy volunteers accepted.

Timeline Started 2023-07 · est. completion 2024-04

Where 4 sites · United States

What this study is testing ClinicalTrials.gov NCT05936138 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3502970 will also be evaluated in these participants. The study will last up to 6 weeks including screening period.

Treatments tested

LY3502970 Drug

Administered orally.

Main thing measured	Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3502970
Sponsor	Eli Lilly and Company
Conditions studied	Renal Insufficiency, Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05936138 ↗